MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia

Blood

Volumn 124, Issue 2, 2014, Pages 263-272

  Manara, Elena ^a   Baron, Emma ^a   Tregnago, Claudia ^a   Aveic, Sanja ^a   Bisio, Valeria ^a   Bresolin, Silvia ^a   Masetti, Riccardo ^b   Locatelli, Franco ^c   Basso, Giuseppe ^a   Pigazzi, Martina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AF6 PROTEIN; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF6 ONCOPROTEIN; ONCOPROTEIN; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHAGY; BLAST CELL; BONE MARROW CELL; CELL CLONE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLONOGENESIS; CONTROLLED STUDY; CYTOPLASM; FUSION GENE; GENE ACTIVATION; GENE EXPRESSION; GENE LOCATION; GENE REARRANGEMENT; GENE SILENCING; HUMAN; HUMAN CELL; MLL AF6 FUSION ONCOGENE; ONCOGENE; PRIORITY JOURNAL; VIRUS ONCOGENE;

CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 6; GENE SILENCING; HUMANS; KINESIN; LEUKEMIA, MYELOID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; MYOSINS; ONCOGENE PROTEINS, FUSION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTIONAL ACTIVATION; TRANSLOCATION, GENETIC;

EID: 84904114990     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-525741     Document Type: Article

References (56)

1. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11): 823-833.
2. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18): 2298-2307.
3. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
4. Pigazzi M, Masetti R, Bresolin S, et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia. 2011;25(3):560-563.
5. Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematol Am Soc Hematol Educ Program. 2011;2011:354-360.
6. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25(8):1239-1248.
7. Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013.
8. Li ZY, Liu DP, Liang CC. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia. 2005;19(2):183-190.
9. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop participants. Leukemia. 1998; 12(5):788-791.
10. Buchert M, Schneider S, Meskenaite V, et al. The junction-associated protein AF-6 interacts and clusters with specific Eph receptor tyrosine kinases at specialized sites of cell-cell contact in the brain. J Cell Biol. 1999;144(2):361-371.
11. Radziwill G, Erdmann RA, Margelisch U, Moelling K. The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol. 2003;23(13):4663-4672.
12. Su L, Hattori M, Moriyama M, et al. AF-6 controls integrin-mediated cell adhesion by regulating Rap1 activation through the specific recruitment of Rap1GTP and SPA-1. J Biol Chem. 2003; 278(17):15232-15238.
13. Takahashi K, Nakanishi H, Miyahara M, et al. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol. 1999; 145(3):539-549.
14. Carmena A, Speicher S, Baylies M. The PDZ protein Canoe/AF-6 links Ras-MAPK, Notch and Wingless/Wnt signaling pathways by directly interacting with Ras, Notch and Dishevelled. PLoS ONE. 2006;1:e66.
15. Radziwill G, Weiss A, Heinrich J, et al. Regulation of c-Src by binding to the PDZ domain of AF-6. EMBO J. 2007;26(11):2633-2644.
16. Kuriyama M, Harada N, Kuroda S, et al. Identification of AF-6 and canoe as putative targets for Ras. J Biol Chem. 1996;271(2): 607-610.
17. Saito S, Matsushima M, Shirahama S, et al. Complete genomic structure DNA polymorphisms, and alternative splicing of the human AF-6 gene. DNA Res. 1998;5(2):115-120.
18. Prasad R, Gu Y, Alder H, et al. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res. 1993; 53(23):5624-5628.
19. Ebnet K, Schulz CU, Meyer Zu Brickwedde MK, Pendl GG, Vestweber D. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J Biol Chem. 2000;275(36):27979-27988.
20. Monroe SC, Jo SY, Sanders DS, et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol. 2011;39(1):77-86.e1-e5.
21. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121(2):167-178.
22. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473-487.
23. Cowell IG, Sondka Z, Smith K, et al. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIß-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci U S A. 2012;109(23):8989-8994.
24. Liedtke M, Ayton PM, Somervaille TC, Smith KS, Cleary ML. Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Blood. 2010; 116(1):63-70.
25. Deshpande AJ, Chen L, Fazio M, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013;121(13):2533-2541.
26. Aveic S, Pigazzi M, Basso G. BAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia. PLoS ONE. 2011;6(10):e26097.
27. Pession A, Masetti R, Rizzari C, et al; AIEOP AML Study Group. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170-178.
28. Sandoval S, Kraus C, Cho E-C, et al. Sox4 cooperates with CREB in myeloid transformation. Blood. 2012;120(1):155-165.
29. Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF III, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol. 2007;383:321-336.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
31. Yamamoto T, Harada N, Kawano Y, Taya S, Kaibuchi K. In vivo interaction of AF-6 with activated Ras and ZO-1. Biochem Biophys Res Commun. 1999;259(1):103-107.
32. Bresolin S, Zecca M, Flotho C, et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol. 2010;28(11):1919-1927.
33. Buchert M, Poon C, King JA, et al. AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartment. J Cell Physiol. 2007; 210(1):212-223.
34. Fournier G, Cabaud O, Josselin E, et al. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Oncogene. 2011;30(36): 3862-3874.
35. Witzig TE, Tang H, Micallef INM, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;118(18):4882-4889.
36. Lancet JE, Duong VH, Winton EF, et al. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011;17(5):1140-1146.
37. Mathew R, Kongara S, Beaudoin B, et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007;21(11):1367- 1381.
38. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007: 4158-4163.
39. Ding H, Hackbarth J, Schneider PA, et al. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood. 2011; 118(18):4872-4881.
40. Ding H, McDonald JS, Yun S, et al. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014;99(1):60-69.
41. Chen S, Xue Y, Zhang X, et al. A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica. 2005;90(6):766-775.
42. Duran A, Linares JF, Galvez AS, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008; 13(4):343-354.
43. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97(11):3589-3595.
44. Berman JN, Gerbing RB, Alonzo TA, et al. Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia. 2011; 25(6):1039-1042.
45. Mahgoub N, Parker RI, Hosler MR, et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer. 1998;21(3):270-275.
46. Liang DC, Shih LY, Fu JF, et al. K-ras mutations and N-ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106(4): 950-956.
47. Ono R, Kumagai H, Nakajima H, et al. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia. 2009;23(12):2197-2209.
48. Kim WI, Matise I, Diers MD, Largaespada DA. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood. 2009;113(5): 1086-1096.
49. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, et al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica. 2013;98(6):937-944.
50. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008;14(8): 2249-2252.
51. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81(1):153-208.
52. Biagi C, Astolfi A, Masetti R, et al. Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. Leukemia. 2010;24(6):1230-1233.
53. Jabbour E, Kantarjian H, Ravandi F, et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011;117(6): 1236-1244.
54. Steensma DP. Novel therapies for myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):423-441.
55. Guo JY, Chen HY, Mathew R, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011; 25(5):460-470.
56. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007; 7(12):961-967.